Tonawanda, NY – March 7, 2024 – Pine Pharmaceuticals, one of the nation's largest and most trusted FDA-registered 503B outsourcing facilities, has announced the launch of moxifloxacin 0.5 mg and 0.75 mg, now available in ready-to-use vials. These latest additions...
Staying current
and connected
See what we are doing, where we are going, and how we are shaping our industry every day.
Pine Pharmaceuticals Announces the Promotion of Gregory Reid to Director of Production
Pine Pharmaceuticals is pleased to announce the promotion of Gregory Reid to Director of Production. Over the past two years, Gregory played a key role in streamlining our operations, particularly during the successful integration of Athenex's 503B business...
Looking Ahead: Exciting Growth and Opportunities for Pine Pharmaceuticals in 2025
The start of 2025 has brought exciting growth and new opportunities for Pine Pharmaceuticals, and we are looking forward to what's ahead. As we move further into the year, we are eager to continue delivering the highest level of service to facilities...
Pine Pharmaceuticals Announces the Promotion of Adam Snyder to Director of Engineering and Maintenance
Pine Pharmaceuticals is thrilled to announce the promotion of Adam Snyder to Director of Engineering and Maintenance. Over the past three years, Adam has played a pivotal role in driving innovation and operational excellence, contributing significantly to Pine's...
2025 Conferences and Trade Shows
April 14 - 16, 2025New Orleans, LALearn more July 29 - August 2, 2025Long Beach, CALearn more December 7 - 11, 2025Las Vegas, NVLearn more
Pine Pharmaceuticals Expands Hospital Offerings with New Norepinephrine 32 mg Premix IV Bag
Tonawanda, NY, December 13, 2024—Pine Pharmaceuticals, one of the nation's largest and most trusted FDA-registered 503B outsourcing facilities, recently announced the launch of norepinephrine 32 mg, the newest addition to its collection of ready-to-administer premix...
Exclusive Interview: Al and Alfonse Reflect on a Decade of Ownership
In continuing Pine's 10th anniversary celebration, we asked Alfonse Muto and Alfonse J. Muto, Pharm.D. ten questions about their decade-long ownership journey and Pine's remarkable evolution. Here's what they had to share: 1. How does it feel to reflect on a decade of...
Celebrating a Decade of Excellence: Pine Pharmaceuticals Marks Its 10th Anniversary
As one of the first facilities to register under section 503B, Pine Pharmaceuticals is celebrating ten years of uncompromising excellence! Founded in 2014 by father and son Alfonse Muto and Alfonse J. Muto, Pharm.D., Pine Pharmaceuticals established itself as an...
Pine Pharmaceuticals named 2023 BioPharma Business of the Year
We are thrilled to announce that Pine Pharmaceuticals has been honored as Buffalo Business First's 2023 Business of the Year in the BioPharma sector! This remarkable achievement is a testament to the unwavering dedication and tireless efforts of our entire team,...
Pine Pharmaceuticals’ Response to USP <797> Updates
On November 1, 2023, the United States Pharmacopeia (USP) introduced significant updates to USP Chapter <797>, a set of guidelines that regulates the integrity of sterile compounding processes in order to prevent microbial contamination and ensure patient...